HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells

Journal of Clinical Investigation

Volumn 127, Issue 12, 2017, Pages 4352-4364

  Veenhuis, Rebecca T ^a   Freeman, Zachary T ^a   Korleski, Jack ^a   Cohen, Laura K ^a   Massaccesi, Guido ^a   Tomasi, Alessandra ^a   Boesch, Austin W ^b   Ackerman, Margaret E ^b   Margolick, Joseph B ^c   Blankson, Joel N ^a   Chattergoon, Michael A ^a   Cox, Andrea L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23P40; INTERLEUKIN 6; INTERLEUKIN 8; IP10 PROTEIN; MCP1 PROTEIN; MIP1 ALPHA PROTEIN; MIP1 PROTEIN; MONOCLONAL ANTIBODY; PROTEIN; RNA; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; TLR7 PROTEIN, HUMAN; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE STAGE; MALE; MEN WHO HAVE SEX WITH MEN; MULTICENTER STUDY; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS UNCOATING; ANTIGEN ANTIBODY COMPLEX; DENDRITIC CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PATHOLOGY; PLASMA CELL;

ANTIGEN-ANTIBODY COMPLEX; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; HIV ANTIBODIES; HIV-1; HUMANS; INTERFERON TYPE I; PLASMA CELLS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 7; VIRAL ENVELOPE PROTEINS;

EID: 85037107592     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI95375     Document Type: Article

References (70)

1. Bosinger SE, Utay NS. Type I interferon: understanding its role in HIV pathogenesis and therapy. Curr HIV/AIDS Rep. 2015;12(1):41–53.
2. Teijaro JR, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340(6129):207–211.
3. Wilson EB, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science. 2013;340(6129):202–207.
4. Sandler NG, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature. 2014;511(7511):601–605.
5. Li G, et al. Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice. PLoS Pathog. 2014;10(7):e1004291.
6. Rotger M, et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest. 2011;121(6):2391–2400.
7. Farzadegan H, et al. Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(5):448–455.
8. Jacquelin B, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest. 2009;119(12):3544–3555.
9. Bosinger SE, et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest. 2009;119 (12):3556–3572.
10. Zhen A, et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. JClinInvest. 2017;127(1):260–268.
11. Cheng L, et al. Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs. J Clin Invest. 2017;127 (1):269–279.
12. Lu LL, et al. A functional role for antibodies in tuberculosis. Cell. 2016;167 (2):433–443.e14.
13. Richter K, Oxenius A. Non-neutralizing antibodies protect from chronic LCMV infection independently of activating FcγR or complement. Eur J Immunol. 2013;43(9):2349–2360.
14. Rerks-Ngarm S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361 (23):2209–2220.
15. Barouch DH, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012;482 (7383):89–93.
16. Beignon AS, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. JClinInvest. 2005;115 (11):3265–3275.
17. Pritschet K, et al. CD4- and dynamin-dependent endocytosis of HIV-1 into plasmacytoid dendritic cells. Virology. 2012;423 (2):152–164.
18. Chattergoon MA, et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 2014;10 (5):e1004082.
19. Campbell EM, Hope TJ. HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol. 2015;13(8):471–483.
20. Rossio JL, et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol. 1998;72(10):7992–8001.
21. McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. JVirol. 2005;79 (1):17–27.
22. O’Brien M, et al. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest. 2011;121 (3):1088–1101.
23. O’Brien M, et al. CD4 receptor is a key determinant of divergent HIV-1 sensing by plasmacytoid dendritic Cells. PLoS Pathog. 2016;12(4):e1005553.
24. Stark GR, Darnell JE. The JAK-STAT pathway at twenty. Immunity. 2012;36(4):503–514.
25. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36–49.
26. Fitzgerald KA, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol. 2003;4(5):491–496.
27. Boesch AW, et al. Highly parallel characterization of IgG Fc binding interactions. MAbs. 2014;6(4):915–92 7.
28. Buchacher A, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electro-fusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses. 1994;10(4):359–369.
29. Moog C, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. MucosalImmunol. 2014;7(1):46–56.
30. Green DS, Lum T, Green JA. IgG-derived Fc down-regulates virus-induced plasmacytoid dendritic cell (pDC) IFN alpha production. Cytokine. 2004;26(5):209–216.
31. Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J. 1989;259(2):347–353.
32. Nesspor TC, Raju TS, Chin CN, Vafa O, Brezski RJ. Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobu-lin G1. JMolRecognit. 2012;25(3):147–154.
33. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. JImmunol. 1989;143(8):2595–2601.
34. Lederle A, et al. Neutralizing antibodies inhibit HIV-1 infection of plasmacytoid dendritic cells by an FcγRIIa independent mechanism and do not diminish cytokines production. Sci Rep. 2014;4:5845.
35. Keir ME, et al. Generation of CD3+CD8low thymocytes in the HIV type 1-infected thymus. JImmunol. 2002;169(5):2788–2796.
36. Cao H, et al. Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain. PLoS ONE. 2012;7(5):e36823.
37. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science. 2007;315(5817):1398–1401.
38. Zhou D, Kang KH, Spector SA. Production of interferon α by human immunodeficiency virus type 1 in human plasmacytoid dendritic cells is dependent on induction of autophagy. J Infect Dis. 2012;205(8):1258–1267.
39. Sauce D, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood. 2011;117(19):5142–5151.
40. Warmerdam PA, van de Winkel JG, Vlug A, West-erdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991;147(4):1338–1343.
41. Musolino A, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008;26(11):1789–1796.
42. Maiga B, et al. Fc gamma receptor IIa-H131R polymorphism and malaria susceptibility in sym-patric ethnic groups, Fulani and Dogon of Mali. Scand J Immunol. 2014;79(1):43–50.
43. Zhang C, Wang W, Zhang H, Wei L, Guo S. Association of FCGR2A rs1801274 polymorphism with susceptibility to autoimmune diseases: A meta-analysis. Oncotarget. 2016;7(26):39436–39443.
44. Rönnblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus. 2008;17(5):394–399.
45. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008;8(8):594–606.
46. Swiecki M, Wang Y, Vermi W, Gilfillan S, Sch-reiber RD, Colonna M. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med. 2011;208(12):2367–2374.
47. Scheid JF, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535(7613):556–560.
48. Bar KJ, et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. NEngl JMed. 2016;375(21):2037–2050.
49. Lynch RM, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7(319):319ra206.
50. Barouch DH, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224–228.
51. Burton DR, Barbas CF, Persson MA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A. 1991;88(22):10134–10137.
52. Barbas CF, et al. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A. 1992;89(19):9339–9343.
53. Burton DR, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science. 1994;266(5187):1024–1027.
54. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. JVirol. 1994;68(8):4821–4828.
55. Walker LM, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–289.
56. Trkola A, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996;70(2):1100–1108.
57. Mascola JR, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. JVirol. 1999;73(5):4009–4018.
58. Etemad-Moghadam B, Sun Y, Nicholson EK, Karls-son GB, Schenten D, Sodroski J. Determinants of neutralization resistance in the envelope glycopro-teins of a simian-human immunodeficiency virus passaged in vivo. JVirol. 1999;73(10):8873–8879.
59. Crawford JM, et al. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. JVirol. 1999;73(12):10199–10207.
60. Stiegler G, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2001;17(18):1757–1765.
61. Purtscher M, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1994;10(12):1651–1658.
62. Purtscher M, et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS. 1996;10(6):587–593.
63. Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A. 1989;86(5):1624–1628.
64. Tyler DS, et al. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. JImmunol. 1990;145(10):3276–3282.
65. Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. JVirol. 1991;65(9):4832–4838.
66. Robinson WE, Gorny MK, Xu JY, Mitchell WM, Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol. 1991;65(8):4169–4176.
67. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126(2):310–318.
68. Detels R, et al. The Multicenter AIDS Cohort Study, 1983 to …. Public Health. 2012;126(3):196–198.
69. Takahashi K, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. Proc Natl Acad Sci U S A. 2010;107 (16):7431–7436.
70. Wasilewski LN, et al. A hepatitis C virus envelope polymorphism confers resistance to neutralization by polyclonal sera and broadly neutralizing monoclonal antibodies. JVirol. 2016;90(7):3773–3782.